Enabling mRNA Delivery: How to Solve LNP Formulation Challenges

Learn how formulating LNPs for the preclinical phase, enabling the safe delivery of mRNA. In this video, Johanna, Principal Scientist at Merck, discuss the challenges in mRNA delivery and lipid nanoparticle (LNP) formulation development, and how to overcome them. Johanna and her teammates specialize in formulating LNPs for the preclinical phase, enabling the safe delivery of mRNA for prevention and treatment of infectious diseases, genetic disorders, and immunotherapy. Discover how our Early Formulation Screening Service can support in developing and optimizing LNP formulations for your nucleic acid payloads. If you're interested in learning more about how to overcome/solve LNP formulation challenges, this video is for you!
For additional information about our LNP CDTMO Services, visit our website: www.sigmaaldrich.com/services/contract-manufacturing/mrna-and-lnp-formulation-ctdmo-services/lipid-nanoparticle-cdmo-services

[@lw1zfog]

‘For us, therefore, we’re really taking that leap - us as company, Bayer, in cell and gene therapy, which to me is one of these examples where really we’re going to make a difference, hopefully, moving forward. Ultimately the mRNA vaccines are an example for that - cell and gene therapy - I always like to say that if we had surveyed two years ago in the public, “would you be willing to take a gene or cell therapy and inject it into your body” - we would have had probably a 95% refusal rate. I think this pandemic has also opened many people’s eyes to innovation in a way that was maybe not possible before.’ - Bayer Executive Stefan Oelrich, in a speech at the World Health Summit, October 2021.

[@deebee4575]

Enjoy clots.